Article
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
The New England journal of medicine - 24 Jul 2008
Cooper David A, Steigbigel Roy T, Gatell Jose M, Rockstroh Jurgen K, Katlama Christine, Yeni Patrick, Lazzarin Adriano, Clotet Bonaventura, Kumar Princy N, Eron Joseph E, Schechter Mauro, Markowitz Martin, Loutfy Mona R, Lennox Jeffrey L, Zhao Jing, Chen Joshua, Ryan Desmond M, Rhodes Rand R, Killar John A, Gilde Lucinda R, Strohmaier Kim M, Meibohm Anne R, Miller Michael D, Hazuda Daria J, Nessly Michael L, DiNubile Mark J, Isaacs Robin D, Teppler Hedy, Nguyen Bach-Yen
Abstract excerpt
BACKGROUND: We evaluated the efficacy of raltegravir and the development of viral resistance in two identical trials involving patients who were infected with human immunodeficiency virus type 1 (HIV-1) with triple-class drug resistance and in whom antiretroviral therapy had failed. METHODS: We conducted subgroup analyses of the data from week 48 in both studies according to baseline prognostic factors....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.